Hyperbaric Oxygen Therapy (HBOT) as a Treatment for COVID-19 (COVID-19) Infection

Ochsner Health System

Overview

Patients who meet inclusion criteria will be randomized into treatment vs control group. Treatment groups will undergo Hyperbaric Oxygen Therapy (HBOT) and compared to the control group.

After enrollment, patients will be randomized into treatment vs control group. Both populations will receive the same inpatient medical treatment. All patients in the treatment group will undergo hyperbaric oxygen therapy under the same treatment protocol. After completion of the treatment protocol, specific study endpoints will be compared between the treatment and control groups.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Conditions

COVID-19

Interventions

Hyperbaric Oxygen TherapyDEVICE

Hyperbaric Oxygen Therapy delivered at a specific uniformed pressure and duration.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult inpatients \>18 years old * Positive PCR COVID-19 testing * CT evidence of interstitial opacity * Oxygen saturation \<90% on room air * pO2 = 55-70. Exclusion Criteria: * Increased oxygen requirements * Hemodynamic instability (MAP\<65) * Bradycardia (HR\<50) * History of seizure disorder * Pneumothorax * GFR\<30 * Hemodialysis * Refractory anxiety/claustrophobia * Current pregnancy * Uncorrectable hypoglycemia

Locations (1)

Ochsner Medical Center

New Orleans, Louisiana, United States

Outcomes

Primary Outcomes

Decrease incidence of intubation by 30% or greater

Compare rates of intubation between treatment and control groups

Time frame: one month

Secondary Outcomes

Decrease renal injury

Measure Glomerular Filtration Rate (GFR) and compare between treatment and control groups

Time frame: one month

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.